Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development Feb 27, 2024
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients Jan 29, 2024
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024 Jan 23, 2024
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients Jan 17, 2024
Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure Dec 11, 2023
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update Nov 14, 2023
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection Nov 2, 2023
Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update Oct 25, 2023
Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences Oct 19, 2023
